Clinical trial · Interventional
Description of the Cystatin C as an Early Nephrotoxic Bio-marker in Pediatric Oncology
Assessment of Cystatin C as a Tubular and Glomerular Marker of Nephrotoxicity in Pediatric Oncology
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cisplatin and ifosfamide are commonly used drugs in chemotherapy. They are known to involve renal toxic threats in children given their immature kidney. This toxicity is increased especially after nephrectomy and/or concomitant radiotherapy. In pediatric oncology, the available evaluation methods of the renal function could be very restrictive to perform on children. In this study, the investigators intend to test the use of the cystatin C as an effective and reliable biological marker of renal toxicity in children treated with cisplatin and / or ifosfamide.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Diseases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Urinary and blood sample for Cystatine dosage | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Urinary and blood sample
- description
- Urinary and blood samples for cystatin C dosage
- interventionNames
- Dietary Supplement: Urinary and blood sample for Cystatine dosage
Primary outcomes (5)
- measure
- Urinary cystatin C rate
- timeFrame
- 1 month
- measure
- Urinary cystatin C rate
- timeFrame
- 6 months
- description
- at T2a and T2b (at the middle of treatment). It can depend on pathology
- measure
- Urinary cystatin C rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Children of 0 to18 years treated with cisplatin and / or ifosfamide in the hematology-oncology unit of Toulouse University Hospital of children regardless to the pathology they have been treated for * Children with more than 4kg * Written informed consent given by both parents or legal representative * Patient covered by a social security agreement Exclusion Criteria: * Impossibility to monitor and follow up the patient until the foreseeable end of the treatment (geographic reasons, etc.) * Contraindication to EDTA clearance performing
References
Publications (1)
- RESULTLambert M, White-Koning M, Alonso M, Garnier A, Alphonsa G, Puiseux C, Munzer C, Berthier J, Malard L, Pasquet M, Chatelut E. Plasma cystatin C is a marker of renal glomerular injury in children treated with cisplatin or ifosfamide. Pediatr Blood Cancer. 2021 Jan;68(1):e28747. doi: 10.1002/pbc.28747. Epub 2020 Oct 15. PMID 33058496